Melanie Thompson

Thomas University — United States

Medicine · Health Sciences

61h-index20.2kcitations174works28.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(112), HIV Research and Treatment(91), HIV/AIDS Research and Interventions(88), HIV-related health complications and treatments(53), Pneumocystis jirovecii pneumonia detection and treatment(10)

Publications170 total

Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process
The Lancet HIV·2025· 3 citedOpen Access
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials
Open Forum Infectious Diseases·2025Open Access
Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel
Annals of Internal Medicine·2025· 11 citedOpen Access
Interpretación intercultural en la jurisprudencia de la Corte Constitucional de Ecuador
Episteme/UNIANDES Episteme·2025Open Access
The CONSENSUS-LAI Study: Establishing Shared Definitions of Virological Failure and Discontinuation for Long-Acting Injectable Cabotegravir and Rilpivirine Therapy
SSRN Electronic Journal·2025Open Access
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 3 citedOpen Access
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
JAMA·2024· 137 cited
Primary Care Guidance for Providers Who Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Clinical Infectious Diseases·2024· 73 citedOpen Access
Ending the HIV Epidemic in Metropolitan Atlanta: a mixed‐methods study to support the local HIV/AIDS response
Journal of the International AIDS Society·2024· 6 citedOpen Access
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel
JAMA·2024· 47 cited
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Queen Mary Research Online (Queen Mary University of London)·2023Open Access
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
JAMA·2022· 524 cited
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series
The Lancet·2022· 142 citedOpen Access
Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Blood·2022
Human Monkeypox Virus Infection in Women During the 2022 Outbreaks – a Global Case Series
SSRN Electronic Journal·2022· 4 citedOpen Access
Erratum to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Clinical Infectious Diseases·2021· 1 cited
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
AIDS·2021· 22 citedOpen Access
Psychosocial Characteristics and Sexual Behaviors of People in Care for HIV Infection: An Examination of Men Who Have Sex with Men, Heterosexual Men and Women
UNC Libraries·2020Open Access
Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study
UNC Libraries·2020Open Access
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
The Lancet HIV·2020· 87 cited
page 1 of 9Next →

Frequent Co-authors

Michael S. Saag(18), Donna M. Jacobsen(16), Paul A. Volberding(13), Margaret A. Fischl(11), Martin Hirsch(11), Douglas D. Richman(11), Scott M. Hammer(10), Robert T. Schooley(10), Patrick Yéni(10), Paul E. Sax(10), Edwin DeJesus(10), Jean‐Michel Molina(10), Joseph J. Eron(8), Pedro Cahn(8), José M. Gatell(8), Joan Montaner(7), Charles C. J. Carpenter(7), David Katzenstein(7), Stefano Vella(7), Constance A. Benson(7)